Form 4 for CORT CORCEPT THERAPEUTICS INC
Accepted 2023-12-05 00:00:00 ET · period of report 2023-12-01 · accession 0000950170-23-068370 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2023-12-05 | 2023-12-01 | CORT | Maduck Sean | See Remarks | M - OptEx | $3.02 | +25.0K | 98.3K | +34% | +$75.4K |
| DMT | 2023-12-05 | 2023-12-01 | CORT | Maduck Sean | See Remarks | A - Grant | $12.98 | +1,164 | 73.9K | +2% | +$15.1K |
| DT | 2023-12-05 | 2023-12-01 | CORT | Maduck Sean | See Remarks | S - Sale+OE | $25.56 | -25.0K | 73.3K | -25% | -$639.0K |
| DMT | 2023-12-05 | 2023-12-01 | CORT | Maduck Sean | See Remarks | M - OptEx | $0.00 | -25.0K | 10.0K | -71% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-01 | M | A | 10,009 | $2.61 | 83,300 | D | — | — | (F1) Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 2 | Common | Common Stock | 2023-12-01 | M | A | 14,991 | $3.29 | 98,291 | D | — | — | (F1) Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 3 | Common | Common Stock | 2023-12-01 | A | A | 582 | $0.00 | 74,455 | D | — | — | (F6) Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. (F1) Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 4 | Common | Common Stock | 2023-12-01 | A | A | 582 | $25.97 | 73,873 | D | — | — | (F4) The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics 2012 Incentive Award Plan on December 1, 2023. (F5) In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. (F1) Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 5 | Common | Common Stock | 2023-12-01 | S | D | 25,000 | $25.56 | 73,291 | D | — | — | (F3) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.47 to $25.785. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. (F1) Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 6 | Derivative | Stock option (right to buy) | 2023-12-01 | M | D | 14,991 | $0.00 | 16,986 | D | $3.29 · — to 2025-02-18 | 14,991 Common Stock | (F9) Fully exercisable. |
| 7 | Derivative | Stock option (right to buy) | 2023-12-01 | M | D | 10,009 | $0.00 | 10,000 | D | $2.61 · — to 2024-08-07 | 10,009 Common Stock | (F9) Fully exercisable. |